Keyword Analysis & Research: netter 1 trial

nih.gov

https://pubmed.ncbi.nlm.nih.gov/34793720/

Overall survival results from the NETTER-1 trial in neuroendocrine tumours: an important milestone Lancet Oncol. 2021 Dec;22(12):1645-1646. doi: 10.1016/S1470-2045(21)00593-3. Epub 2021 Nov 15. Author Irene Virgolini 1 Affiliation 1 Department of Nuclear Medicine, Medizinische Universitat Innsbruck, 6020 Innsbruck, Austria. Electronic address ... Author: Irene Virgolini Publish Year: 2021

Author: Irene Virgolini

Publish Year: 2021

DA: 76 PA: 87 MOZ Rank: 77

onclive.com

https://www.onclive.com/view/netter-1-clinical-trial-overview

Jun 19, 2020 · It was an international study done primarily in Europe and the United States that randomized about 229 patients with midgut neuroendocrine tumors to receive either 177Lu-DOTATATE or a high-dosage...

DA: 59 PA: 88 MOZ Rank: 85

nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1607427

Jan 12, 2017 · We report here results from the phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial, which evaluated the efficacy and safety of 177 Lu … Author: Jonathan Strosberg, G. El-Haddad, Edward Wolin, A. Hendifar, J. Yao, B. Chasen, E. Mittra, P.L. Kunz... Publish Year: 2017

Author: Jonathan Strosberg, G. El-Haddad, Edward Wolin, A. Hendifar, J. Yao, B. Chasen, E. Mittra, P.L. Kunz...

Publish Year: 2017

DA: 40 PA: 32 MOZ Rank: 59

ascopubs.org

https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.4112

In overall conclusion, the NETTER-1 study demonstrated that 177 Lu-DOTATATE yielded a clinically and statistically significant improvement in PFS as a primary endpoint (HR: 0.18, p < 0.0001) as well as a clinically meaningful trend towards improvement in median OS of 11.7 months. No new safety signals emerged during the 5-year long-term follow-up. Author: Jonathan R. Strosberg, Martyn E Caplin, Pamela L. Kunz, Philippe B Ruszniewski, Lisa Bodei, Andrew E... Publish Year: 2021

Author: Jonathan R. Strosberg, Martyn E Caplin, Pamela L. Kunz, Philippe B Ruszniewski, Lisa Bodei, Andrew E...

Publish Year: 2021

DA: 84 PA: 9 MOZ Rank: 81

nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK525556/?report=reader

The NETTER-1 trial was not included in the systematic review in this assessment report as it did not meet the revised inclusion criteria in the updated scope issued by NICE on 18 August 2016. 30 As the NETTER-1 trial is the only RCT to have assessed the effectiveness of 177Lu-DOTATATE, the AG has presented the findings from the trial here.

DA: 73 PA: 57 MOZ Rank: 49

thelancet.com

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00593-3/fulltext

Nov 15, 2021 · The primary objective of the NETTER-1 trial was met in 2017, showing a significantly longer progression-free survival in patients with these tumours following treatment with 177 Lu-Dotatate in combination with long-acting octreotide (20–30 mg) versus high-dose (60 mg) long-acting octreotide alone (p=0·0001).

DA: 33 PA: 15 MOZ Rank: 26

ascopubs.org

https://ascopubs.org/doi/abs/10.1200/jco.2016.34.4_suppl.194

Feb 01, 2016 · Methods: NETTER-1 is the first Phase III multicentric, randomized, controlled trial evaluating 177 Lu-DOTA 0-Tyr 3-Octreotate (Lutathera) in patients with inoperable, progressive, somatostatin receptor positive midgut NETs. 230 patients with Grade 1-2 metastatic midgut NETs were randomized to receive Lutathera 7.4 GBq every 8 weeks (x4 ...

DA: 27 PA: 45 MOZ Rank: 22

nih.gov

https://pubmed.ncbi.nlm.nih.gov/29878866/

Sep 01, 2018 · Methods The NETTER-1 trial is an international phase III study in patients with midgut NETs. Patients were randomly assigned to treatment with 177Lu-Dotatate versus high-dose octreotide.

DA: 42 PA: 14 MOZ Rank: 85

snmjournals.org

https://jnm.snmjournals.org/content/57/supplement_2/629

May 01, 2016 · Conclusions The phase III NETTER-1 trial provides evidence for a clinically meaningful and statistically significant increase in PFS and ORR, and suggests an OS benefit in patients with advanced midgut NETs treated with 177Lu-Dotatate. 177Lu-Dotatate safety profile was found to be very favorable, with no clinically relevant findings especially ...

DA: 37 PA: 39 MOZ Rank: 75

nejm.org

https://www.nejm.org/doi/pdf/10.1056/NEJMoa1607427

Jan 12, 2017 · endocrine Tumors Therapy (NETTER-1) trial, which evaluated the efficacy and safety of 177Lu- Dotatate as compared with high-dose octreotide long-acting repeatable (LAR) in patients with advanced,...

DA: 64 PA: 88 MOZ Rank: 55